Related Experiment Video
Updated: Mar 22, 2026

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
Published on: September 30, 2016
NF-κB decoy polyplexes decrease P-glycoprotein-mediated multidrug resistance in colorectal cancer cells
N H Abd Ellah1,2, L Taylor3, N Ayres3
1James L. Winkle College of Pharmacy, University of Cincinnati, Cincinnati, OH, USA.
Abstract:
Multidrug resistance (MDR), a major cause for chemotherapy failure, has been linked to upregulation of ATP-dependent membrane efflux systems that limit intracellular accumulation of cytotoxic anticancer agents. P-glycoprotein (P-gp) encoded by the human ABCB1 gene was the first efflux transporter identified to contribute to MDR. ABCB1 gene expression is correlated with constitutive activation of the NF-κB signaling pathway in tumor cells. The objective of this research is to modulate P-gp activity in colon cancer cells using NF-κB decoy oligodeoxynucleotides (ODNs) that are effectively delivered into the nucleus of colorectal cancer cells by self-assembling nonviral nanoparticles comprising the novel poly[N-(2-hydroxypropyl)methacrylamide]-poly(N,N-dimethylaminoethylmethacrylate) diblock copolymer (pHPMA-b-pDMAEMA). Ethidium bromide intercalation and gel retardation assays demonstrated high DNA condensation capacity of pHPMA-b-pDMAEMA. Nanoparticles prepared with and without decoy ODNs did not significantly compromise cellular safety at N/P ratios ⩽4. Transfection efficiency of pHPMA-b-pDMAEMA polyplexes (N/P=4) in Caco-2 cells was comparable to TurboFect transfection standard, resulting in a 98% reduction in P-gp protein levels. As a pharmacodynamic consequence, intracellular accumulation of the P-gp substrate Rhodamine123 significantly increased by almost twofold. In conclusion, NF-κB ODN polyplexes fabricated with pHPMA-b-pDMAEMA polymer effectively reduced P-gp-mediated efflux activity in Caco-2 cells, suggesting successful interference with NF-κB-binding sites in the promoter region of the ABCB1 gene.
Insights
This study developed novel nanoparticles to deliver NF-κB decoy oligodeoxynucleotides (ODNs) into colon cancer cells. This effectively reduced P-glycoprotein (P-gp) levels and increased chemotherapy drug accumulation, overcoming multidrug resistance.
Area of Science:
- Biomedical Engineering
- Cancer Biology
- Nanotechnology
Background:
- Multidrug resistance (MDR) in cancer chemotherapy is often caused by efflux pumps like P-glycoprotein (P-gp).
- P-gp expression is regulated by the NF-κB signaling pathway in tumor cells.
- Targeting P-gp and NF-κB is a strategy to overcome MDR.
Purpose of the Study:
- To develop a nanoparticle-based system for delivering NF-κB decoy oligodeoxynucleotides (ODNs) into colorectal cancer cells.
- To modulate P-gp expression and activity in colon cancer cells.
- To assess the efficacy of this approach in overcoming P-gp-mediated multidrug resistance.
Main Methods:
- Fabrication of self-assembling nonviral nanoparticles using a novel poly[N-(2-hydroxypropyl)methacrylamide]-poly(N,N-dimethylaminoethylmethacrylate) diblock copolymer (pHPMA-b-pDMAEMA).
- Evaluation of DNA condensation capacity and cellular safety of the nanoparticles.
- Transfection of Caco-2 cells with NF-κB decoy ODN-loaded nanoparticles.
- Quantification of P-gp protein levels and assessment of intracellular accumulation of Rhodamine123.
Main Results:
- pHPMA-b-pDMAEMA nanoparticles demonstrated high DNA condensation capacity and good cellular safety.
- Transfection efficiency in Caco-2 cells was comparable to commercial standards, achieving a 98% reduction in P-gp protein levels.
- Intracellular accumulation of Rhodamine123, a P-gp substrate, increased nearly twofold.
Conclusions:
- NF-κB ODN polyplexes formulated with pHPMA-b-pDMAEMA effectively reduce P-gp-mediated efflux activity in colon cancer cells.
- This approach successfully interferes with NF-κB binding sites in the ABCB1 gene promoter.
- The developed nanoparticle system shows promise for overcoming P-gp-mediated multidrug resistance in cancer therapy.
More Related Videos
06:49Orthotopic Implantation of Patient-Derived Cancer Cells in Mice Recapitulates Advanced Colorectal Cancer
Published on: February 10, 2023
14:20Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
Published on: June 13, 2014